// App-Quantinova.ai

85 : Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosisa - the Surprise Trial

Researchers

Presenter

  • Jan Beyer-Westendorf

Principal Investigators

  • Sebastian Schellong

  • Horst Gerlach

  • Katja Jersemann

  • Eberhard Rabe

  • Kurtulus Sahin

  • Rupert Bauersachs

Medical Centers

  • Private Office for Vascular Diseases, Mannheim, Germany

  • Center for Vascular Diseases, Division Thrombosis Research,, University Hospital Carl Gustav Carus,, Dresden, Germany

  • GWT-TUD GmbH, Dresden, Germany

  • Municipal Hospital Friedrichstadt, Dresden, Germany

  • University Hospital Bonn, Bonn, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Fondaparinux sodium

  • rivaroxaban

Outcome

  • N/A

Study Design

  • observational

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved